Eris Lifesciences Allots 19,624 Equity Shares Under ESOP-2021 Scheme
Eris Lifesciences Limited allotted 19,624 equity shares on March 12, 2026, under the ESOP-2021 scheme from grants made in 2022 (3,839 shares at Rs. 557.24), 2023 (7,776 shares at Rs. 510.32), and 2024 (8,009 shares at Rs. 728.16). The allotment increased the company's paid-up share capital from Rs. 13,85,23,263 to Rs. 13,85,42,887, with total equity shares rising to 13,85,42,887 shares of Re. 1 each.
*this image is generated using AI for illustrative purposes only.
Eris lifesciences Limited has completed the allotment of 19,624 equity shares on March 12, 2026, under its Employee Stock Option Plan (ESOP-2021) scheme. The pharmaceutical company informed both BSE Limited and National Stock Exchange of India Limited about this corporate action through an official communication.
ESOP Allotment Details
The allotment encompasses shares from employee stock options granted across three consecutive years under the ESOP-2021 scheme. The breakdown demonstrates varying exercise prices reflecting different grant periods and market conditions at the time of grant.
| Grant Year | Shares Allotted | Issue Price per Share |
|---|---|---|
| 2022 | 3,839 | Rs. 557.24 |
| 2023 | 7,776 | Rs. 510.32 |
| 2024 | 8,009 | Rs. 728.16 |
| Total | 19,624 | Variable |
Impact on Share Capital
The allotment has resulted in an increase in the company's paid-up share capital structure. The capital expansion reflects the conversion of employee stock options into equity shares, which is a standard practice under ESOP schemes.
| Parameter | Before Allotment | After Allotment |
|---|---|---|
| Paid-up Capital | Rs. 13,85,23,263 | Rs. 13,85,42,887 |
| Number of Shares | 13,85,23,263 | 13,85,42,887 |
| Face Value per Share | Re. 1 | Re. 1 |
Corporate Communication
The allotment information was communicated to the stock exchanges by Milind Talegaonkar, Company Secretary and Compliance Officer, as part of the company's regulatory disclosure obligations. The communication was digitally signed and dated March 12, 2026, ensuring proper documentation and compliance with exchange requirements.
This ESOP exercise represents the conversion of employee stock options into equity shares, allowing eligible employees to become shareholders in the pharmaceutical company. The varying exercise prices across different grant years reflect the market conditions and company valuation at the respective times of grant under the ESOP-2021 scheme.
Historical Stock Returns for Eris Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.24% | -0.40% | -7.94% | -20.40% | +6.67% | +131.89% |
20
